Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres
Authors:
- 5 March 2014
- journal article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (8) , 2033-2037
Abstract
Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide–docetaxel). The resultant reduction in FN rate is thought to maintain dose intensity and improve patient experience. This retrospective study was performed to assess whether the addition of G-CSF primary prophylaxis into daily clinical practice has achieved these aims.Keywords
This publication has 13 references indexed in Scilit:
- Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysisSupportive Care in Cancer, 2012
- Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centreAnnals of Oncology, 2011
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applicationsAnnals of Oncology, 2010
- Impact of effective prevention and management of febrile neutropeniaBritish Journal of Cancer, 2009
- Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy2009
- Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 TrialJournal of Clinical Oncology, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III StudyJournal of Clinical Oncology, 2005
- First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III StudyJournal of Clinical Oncology, 2005
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995